PO:14:195 | Real-world effectiveness of anifrolumab in achieving treatment targets and reducing systemic lupus erythematosus disease burden: 6-month interim analysis of the REVEAL study
Background. Following the recent approval of anifrolumab (ANI) for the treatment of moderate-to-severe Systemic Lupus Erythematosus (SLE), real-world data remain limited beyond those from clinical trials. Real-world eVidencE of Anifrolumab in systemic Lupus erythematosus (REVEAL) is a 5-years, mult...
Gespeichert in:
| 1. Verfasser: | |
|---|---|
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
PAGEPress Publications
2025-11-01
|
| Schriftenreihe: | Reumatismo |
| Schlagworte: | |
| Online-Zugang: | https://www.reumatismo.org/reuma/article/view/2031 |
| Tags: |
Keine Tags, Fügen Sie das erste Tag hinzu!
|